|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Global Market Report of Human GLP-1 (7-37) (CAS 106612-94-6) December 2024 Global Market Report of GLP-2 (HUMAN) (CAS 223460-79-5) December 2024 CAS 106612-94-6 Human GLP-1 (7-37) Chemical Report & Database ... & Database definitions: Name: Human GLP-1 (7-37): Human-GLP-1-7-37; 7-37-Glucagon-like peptide I (human); Insulinotropin (human); Peptide GLP-1 (human glucose-lowering ... Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012 This report “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012” published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A ... Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class Bydureon – A near term growth driver of the class Novel delivery platforms and fixed dose combination of GLP-1’s + Insulin will drive growth in longer term This decade of the ... Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 ... , recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, anticoagulants, Aflibercept, GLP-1 antagonist ... among market players), opportunities (launch of GLP-1 biosimilars, increasing strategic partnerships and ... Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031 The Human Microbiome market is expected to reach USD 7.09 billion in 2031 from USD 1.40 billion in 2024, at a CAGR of 31.0% during the forecast period. Factors such as the collaborative efforts between the microbiome industry and academia for microbiome ... Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020 ... products and the phasing out of human insulin are some key factors ... ) Alpha-glucosidase inhibitors Biguanides Sulphonylureas GLP-1 agonist Meglitinides DPP-4 inhibitors SGLT ... Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim) Global diabetes drug market is expected to surpass US$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market. Type 2 diabetes is on the rise ... In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030 ... mouse model capable of producing fully human nanobodies, with their advanced in ... tfacilitate the extensive development of fully human nanobody drugs. In VivCRO Market Report ... expected tdrive segment growth The GLP toxicology segment dominated the market ... Global GLP-1 Agonist Market Growth 2025-2031 ... CAGR of 17.2% from 2025 to 2031. GLP-1 is a polypeptide hormone secreted by the intestine ... sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl ... and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can ... Global GLP-1 Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029 ... sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl ... and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can ... total of 15 chapters: Chapter 1, to describe GLP-1 Agonist product scope, market ... Global GLP-1 Agonist Supply, Demand and Key Producers, 2023-2029 ... sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl ... and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can ... well as details the characteristics of GLP-1 Agonist that contribute to its increasing ... Mutagenicity Testing and Genotoxicity Testing Market by Type of Assay (In vivo, In vitro and Non-GLP / Screening), Assay / Test Offered (Comet Assay, Micronucleus Assay, Chromosomal Aberration Test, Genetic Mutation Test and Others), End User Industry (Chemical Industry, Healthcare Industry, Agriculture Industry, Cosmetic Industry and Other Industries) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 The mutagenicity testing and genotoxicity testing market is expected to reach USD 1.01 billion in 2023 anticipated to grow at a CAGR of 7% during the forecast period 2023-2035. Genotoxicity signifies the potential of harmful agents across physical, ... Preclinical CRO Market Size, Trends, Analysis, and Outlook By Service (Bioanalysis and DMPK studies(In vitro ADME, In-vivo PK), Toxicology Testing(GLP, Non-GLP), Compound Management(Process R&D, Custom Synthesis, Others), Chemistry(Medicinal Chemistry, Computation Chemistry), Safety Pharmacology, Others), By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), By End-user (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies), by Region, Country, Segment, and Companies, 2024-2030 ... ADME, In-vivo PK), Toxicology Testing(GLP, Non-GLP), Compound Management(Process R&D, ... in translational research models, such as humanized animal models and organ-on-a- ... ADME -In-vivo PK Toxicology Testing -GLP -Non-GLP Compound Management -Process R&D - ... Injectable Anti diabetic Drugs Market Size, Trends, Analysis, and Outlook By Insulin, Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins), By Glucagon-like peptide-1 (GLP-1) agonists drugs, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide), by Country, Segment, and Companies, 2024-2032 ... Human Insulins, Combination Insulins, Biosimilar Insulins), By Glucagon-like peptide-1 (GLP-1) ... long-acting insulin analogs, GLP-1 receptor agonists, and amylin ... Human Insulins Combination Insulins Biosimilar Insulins By Glucagon-like peptide-1 (GLP-1) ... In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2025-2033 ... living organism and conducts human clinical trials to assess the ... the market based on type, GLP type and indication. Breakup ... Rodent Breakup by GLP Type: Non-GLP In House Outsourcing GLP Toxicology In House ... CRO market based on the GLP type? 7.What is the ... Diabetes Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others), By Diabetes Type (Type 1, Type 2, Gestational), By Route of Administration (Oral, Subcutaneous, Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Others), By Region and Competition, 2020-2030F ... of newer classes of drugs, such as GLP-1 receptor agonists (e.g., Liraglutide and ... on strengthening healthcare infrastructure, developing human resources, and promoting health ... introduction of innovative therapies such as GLP-1 receptor agonists and SGLT2 ... Recombinant Human Insulin Market Forecasts to 2030 – Global Analysis By Product (Short-Acting Human Insulin, Intermediate-Acting Human Insulin and Premixed Human Insulin), Brand (Humulin R, Novolin R, Humulin N, Novolin N and Other Brands), Distribution Channel and By Geography ... Strict regulatory oversight of recombinant human insulin products results in lengthy ... Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes ... Short-Acting Human Insulin Intermediate-Acting Human Insulin Premixed Human Insulin ... GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the ... |